This company has been marked as potentially delisted and may not be actively trading. ERYTECH Pharma (ERYP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ERYP vs. IKT, PLX, CVM, ZIVO, IZTC, CRTX, JATT, ALVR, FNCH, and NKGNShould you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), CEL-SCI (CVM), ZIVO Bioscience (ZIVO), Invizyne Technologies (IZTC), Cortexyme (CRTX), JATT Acquisition (JATT), AlloVir (ALVR), Finch Therapeutics Group (FNCH), and NKGen Biotech (NKGN). These companies are all part of the "medical" sector. ERYTECH Pharma vs. Its Competitors Inhibikase Therapeutics Protalix BioTherapeutics CEL-SCI ZIVO Bioscience Invizyne Technologies Cortexyme JATT Acquisition AlloVir Finch Therapeutics Group NKGen Biotech ERYTECH Pharma (NASDAQ:ERYP) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation. Does the media refer more to ERYP or IKT? In the previous week, ERYTECH Pharma's average media sentiment score of 0.00 equaled Inhibikase Therapeutics'average media sentiment score. Company Overall Sentiment ERYTECH Pharma Neutral Inhibikase Therapeutics Neutral Do insiders & institutionals hold more shares of ERYP or IKT? 1.1% of ERYTECH Pharma shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 1.9% of ERYTECH Pharma shares are owned by company insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher earnings & valuation, ERYP or IKT? ERYTECH Pharma has higher revenue and earnings than Inhibikase Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioERYTECH Pharma$32.66M3.24-$240KN/AN/AInhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.58 Is ERYP or IKT more profitable? ERYTECH Pharma's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ERYTECH PharmaN/A N/A N/A Inhibikase Therapeutics N/A -350.63%-201.82% Which has more volatility & risk, ERYP or IKT? ERYTECH Pharma has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Do analysts rate ERYP or IKT? Inhibikase Therapeutics has a consensus target price of $6.50, indicating a potential upside of 322.08%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Inhibikase Therapeutics is more favorable than ERYTECH Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ERYTECH Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryERYTECH Pharma and Inhibikase Therapeutics tied by winning 5 of the 10 factors compared between the two stocks. Get ERYTECH Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERYP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERYP vs. The Competition Export to ExcelMetricERYTECH PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.77M$285.60M$5.78B$10.04BDividend YieldN/AN/A5.27%4.52%P/E RatioN/AN/A75.5726.08Price / Sales3.24450.05516.51171.66Price / CashN/A22.4437.2059.76Price / Book3.8810.4911.536.20Net Income-$240K-$115.81M$3.29B$270.65M ERYTECH Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERYPERYTECH PharmaN/A$3.10flatN/AN/A$105.77M$32.66M0.0049IKTInhibikase Therapeutics1.5243 of 5 stars$1.75-0.9%$6.50+272.5%+21.0%$130.41MN/A-0.666PLXProtalix BioTherapeutics3.057 of 5 stars$1.64-0.3%$15.00+817.4%+70.3%$130.36M$61.95M-12.58200Positive NewsCVMCEL-SCI0.846 of 5 stars$11.74-3.5%N/A-66.2%$80.75MN/A-24.4443News CoveragePositive NewsShort Interest ↑ZIVOZIVO Bioscience0.1606 of 5 stars$17.00-2.9%N/A+1.9%$64.89M$15.85K-3.4810News CoverageGap UpIZTCInvizyne TechnologiesN/A$9.70flatN/AN/A$60.64MN/A0.0029CRTXCortexymeN/A$1.60flatN/A+124.9%$48.24MN/A-0.5455JATTJATT AcquisitionN/A$2.02-1.0%N/A-39.0%$34.85MN/A0.003High Trading VolumeALVRAlloVirN/A$4.00-2.0%N/A-72.9%$20.17MN/A-0.20110Gap DownHigh Trading VolumeFNCHFinch Therapeutics GroupN/A$12.03-7.5%N/A+1.0%$19.32MN/A-1.36190NKGNNKGen Biotech0.1632 of 5 stars$0.20+50.9%N/A-83.6%$8.99MN/A-0.04N/ANews Coverage Related Companies and Tools Related Companies IKT Alternatives PLX Alternatives CVM Alternatives ZIVO Alternatives IZTC Alternatives CRTX Alternatives JATT Alternatives ALVR Alternatives FNCH Alternatives NKGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERYP) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ERYTECH Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share ERYTECH Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ERYP Stock Alerts